Positive Pre-dose in subsequent period of long acting depot injection [Design Issues]

posted by Compliance – India, 2015-10-14 14:54 (3901 d 11:13 ago) – Posting: # 15559
Views: 9,353

Dear All,

Does FDA raise any concern if we get around 20 to 25% positive pre-dose concentration in subsequent period of the study? Please note that the product is long acting depot injection and wash out duration fixed based on the data available on FDA site under SBOA for reference product.

Please share your advice/ comment in this regard.

Regards,

Compliance

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
136 visitors (0 registered, 136 guests [including 15 identified bots]).
Forum time: 02:08 CEST (Europe/Vienna)

I have finally come to the konklusion
that a good reliable set ov bowels
iz worth more to a man
than enny quantity of brains.    Josh Billings

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5